Rating Change
William Blair analysts initiated coverage on Palvella Therapeutics, Inc. (NASDAQ:PVLA) with a rating of Outperform on October 16, 2026.
new coverageNASDAQ:PVLA
William Blair Initiates Coverage on Palvella Therapeutics, Inc. (PVLA) with Outperform
William Blair analysts initiated coverage on Palvella Therapeutics, Inc. (NASDAQ:PVLA) with a rating of Outperform on October 16, 2026.
At publication ·
What changed
Palvella Therapeutics, Inc. (NASDAQ:PVLA) · new coverage
- Firm
- William Blair
- Rating
- Outperform
- Price at event
- $120.30
- Market capitalization
- $1.1B
At a glance
Key takeaways
- William Blair initiated coverage on Palvella Therapeutics with an Outperform rating on October 16, 2026.
- The stock trades at $120.30 with a market capitalization of $1.1 billion.
Market Context
Palvella Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $120.30 with a market capitalization of $1.1B.
Analyst coverage from William Blair provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Palvella Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Palvella Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 16, 2026 | William Blair | Outperform | N/A |
| Oct 12, 2026 | HC Wainwright & Co. | Buy | N/A |
| Sep 21, 2026 | Chardan Capital | Buy | N/A |
| May 21, 2026 | Stephens & Co. | Overweight | N/A |
| May 21, 2026 | Chardan Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View PVLA Stock Page
Frequently Asked Questions
What does the Outperform rating mean for PVLA?
A rating of Outperform from William Blair reflects the analyst's outlook on Palvella Therapeutics, Inc. (NASDAQ:PVLA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the PVLA forecast page.